

Person—type of opioid pharmacotherapy treatment, code N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Person—type of opioid pharmacotherapy treatment, code N

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Type of opioid pharmacotherapy treatment
METEOR identifier:	696815
Registration status:	Health , Standard 29/05/2024
Definition:	The type of opioid pharmacotherapy administered to a person, as represented by a code.
Data Element Concept:	Person—type of opioid pharmacotherapy treatment
Value Domain:	Type of opioid pharmacotherapy treatment code N

Value domain attributes

Representational attributes

Representation class:	Code
Data type:	Number
Format:	N
Maximum character length:	1

	Value	Meaning
Permissible values:	1	Methadone
	2	Buprenorphine-naloxone
	3	Buprenorphine long-acting injection
	4	Buprenorphine
	5	Naltrexone

Collection and usage attributes

Guide for use:	<p>CODE 1 Methadone</p> <p>Includes treatment programs whereby the administered opioid substitute is methadone.</p> <p>CODE 2 Buprenorphine-naloxone</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine-naloxone such as Suboxone.</p> <p>CODE 3 Buprenorphine long-acting injection</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine long-acting injection such as Buvidal, Sublocade.</p> <p>CODE 4 Buprenorphine</p> <p>Includes treatment programs whereby the administered opioid substitute is buprenorphine such as Subutex, Probuphine.</p> <p>CODE 5 Naltrexone</p> <p>Includes treatment programs whereby the administered opioid substitute is naltrexone.</p>
-----------------------	---

Comments: Opiate substitution programs use a long-acting synthetic opiate medication, usually methadone or levo-alpha acetyl methadol, administered orally for a sustained period at a dosage sufficient to prevent opiate withdrawal, block the effects of illicit opiate use and decrease opiate craving.

Source and reference attributes

Submitting organisation:	Australian Institute of Health and Welfare
Reference documents:	Australian Institute of Health and Welfare (2022) National Opioid Pharmacotherapy Statistics Annual Data collection , AIHW, Australian Government, accessed 21 September 2022.

Data element attributes

Collection and usage attributes

Guide for use:	This data element should be used in conjunction with the data elements: Person—previous opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N and Person—current opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N to provide information on a person's history of opioid pharmacotherapy treatment.
-----------------------	--

Source and reference attributes

Submitting organisation:	Australian Institute of Health and Welfare
Reference documents:	<p>Dolan KA, Hall W & Wodak A 1996. Methadone maintenance reduces injecting in prison. <i>British Medical Journal</i> 312:1162.</p> <p>Australian Institute of Health and Welfare (2022) National Opioid Pharmacotherapy Statistics Annual Data collection, AIHW, Australian Government, accessed 21 September 2022.</p>

Relational attributes

Related metadata references:

Supersedes [Person—type of opioid pharmacotherapy treatment, code N](#)
[Health](#), Superseded 29/05/2024

See also [Person—current opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N](#)
[Health](#), Standard 29/05/2024

See also [Person—previous opioid pharmacotherapy treatment program indicator, prisoner health yes/no/unknown code N](#)
[Health](#), Standard 29/05/2024

See also [Prison dischargee—opioid substitution program continuation on release indicator, prisoner health yes/no/unknown code N](#)
[Health](#), Standard 28/04/2016

Implementation in Data Set Specifications:

[Opioid pharmacotherapy treatment cluster \(entrant\)](#)
[Health](#), Standard 29/05/2024

Conditional obligation:

Conditional on the respondent indicating that they are currently on, or have been on a pharmacotherapy for opioid dependence.

[Opioid pharmacotherapy treatment program cluster \(dischargee\)](#)
[Health](#), Standard 29/05/2024